Octavio Espinoza Ligand Pharmaceuticals Inc (LGND) insider trading activity

LGND Quotes by TradingView

Octavio Espinoza is Chief Financial Officer of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 24,610 shares of LGND, which is worth approximately $3.02 Million. The most recent transaction as insider was on Sep 20, 2024, when has been sold 1,275 shares (Common Stock) at a price of $103.93 per share, resulting in proceeds of $132,510. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24.6K
0.86% 3M change
1.82% 12M change
Total Value Held $3.02 Million

Octavio Espinoza Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 20 2024
SELL
Open market or private sale
$132,510 $103.93 p/Share
1,275 Reduced 4.93%
24,610 Common Stock
Sep 17 2024
BUY
Exercise of conversion of derivative security
$102,489 $68.97 p/Share
1,486 Added 5.43%
25,885 Common Stock
Aug 28 2024
BUY
Exercise of conversion of derivative security
$47,913 $63.63 p/Share
753 Added 2.99%
24,399 Common Stock
Jun 28 2024
BUY
Other acquisition or disposition
$16,209 $60.71 p/Share
267 Added 1.12%
23,646 Common Stock
May 17 2024
SELL
Open market or private sale
$446,818 $86.66 p/Share
5,156 Reduced 18.07%
23,379 Common Stock
May 17 2024
BUY
Exercise of conversion of derivative security
$419,239 $60.61 p/Share
6,917 Added 19.51%
28,535 Common Stock
May 16 2024
SELL
Open market or private sale
$194,704 $86.0 p/Share
2,264 Reduced 9.48%
21,618 Common Stock
May 15 2024
SELL
Open market or private sale
$505,136 $86.01 p/Share
5,873 Reduced 19.74%
23,882 Common Stock
Feb 28 2024
SELL
Open market or private sale
$12,384 $88.46 p/Share
140 Reduced 0.47%
29,755 Common Stock
Feb 28 2024
BUY
Exercise of conversion of derivative security
$72,237 $57.15 p/Share
1,264 Added 4.06%
29,895 Common Stock
Feb 27 2024
BUY
Grant, award, or other acquisition
-
7,208 Added 20.11%
28,631 Common Stock
Feb 15 2024
SELL
Payment of exercise price or tax liability
$110,407 $74.65 p/Share
1,479 Reduced 6.46%
21,423 Common Stock
Dec 05 2023
SELL
Payment of exercise price or tax liability
$75,645 $59.61 p/Share
1,269 Reduced 5.25%
22,902 Common Stock
Oct 01 2023
SELL
Payment of exercise price or tax liability
$20,732 $59.92 p/Share
346 Reduced 1.41%
24,171 Common Stock
Jun 30 2023
BUY
Other acquisition or disposition
$21,292 $56.78 p/Share
375 Added 1.51%
24,517 Common Stock
Feb 23 2023
BUY
Grant, award, or other acquisition
-
6,046 Added 20.03%
24,142 Common Stock
Feb 15 2023
SELL
Payment of exercise price or tax liability
$61,960 $72.98 p/Share
849 Reduced 4.48%
18,096 Common Stock
Dec 30 2022
BUY
Other acquisition or disposition
$15,614 $56.78 p/Share
275 Added 1.43%
18,945 Common Stock
Dec 13 2022
BUY
Grant, award, or other acquisition
-
11,000 Added 37.07%
18,670 Common Stock
Nov 30 2022
SELL
Payment of exercise price or tax liability
$86,532 $72.9 p/Share
1,187 Reduced 13.4%
7,670 Common Stock
Nov 09 2022
SELL
Open market or private sale
$128,285 $75.64 p/Share
1,696 Reduced 16.07%
8,857 Common Stock
OE

Octavio Espinoza

Chief Financial Officer
San Diego, CA

Track Institutional and Insider Activities on LGND

Follow LIGAND PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

News

Receive news related to LIGAND PHARMACEUTICALS INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on LGND